Sanaria
Sanaria

WELCOME TO SANARIA

Sanaria is a biotechnology company developing vaccines protective against malaria. Sanaria’s vaccines have proven highly protective in humans.
Learn more

Malaria is responsible for more childhood mortality than any other single infectious agent. Sanaria’s vaccine development efforts are focused on African children, the population most urgently in need of protection.
Learn more

To subscribe to our mailing list email SUBSCRIBE to sanaria@sanaria.com

Sanaria

The International PfSPZ Consortium (I-PfSPZ-C) held its semi-annual meeting at the University of Maryland School of Medicine in Baltimore on 9th and 10th November. This meeting saw record attendance of malaria researchers associated with Sanaria's PfSPZ program with 145 attendees from 44 institutions in 14 countries present in the room and more people joining online from around the world.

Meeting Agenda
Learn more
Sanaria

The First International Conference for the development of a vaccine against malaria in Equatorial Guinea was held in October 2017 in Equatorial Guinea.

Sanaria

The International PfSPZ Consortium (I-PfSPZ-C) held its semi-annual meeting in Atlanta on November 10-11, 2016. More than 100 investigators from 35 organizations in 18 countries attended and presented the status and results of ongoing and recently completed, but unpublished, clinical trials of Sanaria® PfSPZ Vaccine, PfSPZ-CVac and PfSPZ Challenge in Tanzania, Kenya, Mali, Burkina Faso, Equatorial Guinea, Germany and multiple sites in the United States.

Sanaria

Sanaria's CEO, Dr. Stephen L. Hoffman, awarded the Weill Cornell Medicine Alumni Association Award of Distinction for his significant accomplishments as a physician, scientist and entrepreneur.

Commencement Specch
SanariaSanaria's manufacturing facility

Nature Medicine publishes Sanaria's Research Article, Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

Sanaria Press Release
NIH Press Release
NBC News
New York Times
Press Coverage
SanariaPhoto Credit: Annie Leibovitz

Sanaria's CEO, Dr. Stephen L. Hoffman, and Exec VP of Manufacturing and Process Development, Dr. B. Kim Lee Sim, featured in an Annie Leibovitz photo shoot sponsored by the Bill and Melinda Gates Foundation, The Art of Saving a Life - Vaccine Heroes.

Learn more
Video
Huffington Post

What happens inside humans when a mosquito bites

Choumet, et al, PLOS 2012
National Geographic

If you are interested in joining our team, please check our employment openings.

If you are interested in information about enrollment or participation in Sanaria's clinical trials, please contact us.

Follow sanaria_inc on Twitter

 

Sanaria

November 2017
Building upon publication of clinical trial results in Nature, PNAS, Lancet Infectious Diseases, and JCI Insight in 2017, Sanaria Inc. is highlighting the work of its many collaborators at a symposium entitled "Moving Toward a PfSPZ Malaria Vaccine for Protecting Travelers and Use in Elimination Campaigns" at the 66th meeting of the American Society of Tropical Medicine and Hygiene in Baltimore, and then at the second 2017 International PfSPZ Consortium meeting held at the University of Maryland School of Medicine: Sanaria Press Release

November 2017
The American Journal of Tropical Medicine and Hygiene publishes Article, Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoites Vaccine for Malaria in Healthy Equatoguinean Men: Abstract

February 2017
In a PNAS report, Sanaria's, Attenuated PfSPZ Vaccine induces strain- transcending T cells and durable protection against heterologous controlled human malaria infection: Abstract; Sanaria Press Release

February 2017
The Lancet Infectious Diseases report describes sustained protection with PfPSZ Vaccine, Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed Malian adults: a randomised, double-blind trial: Article; Sanaria Press Release

February 2017
Nature publishes Sanaria's Article, Sterile protection against human malaria by chemoattenuated PfSPZ vaccine: Abstract; Full Article; Sanaria Press Release

January 2017
The Foundation for Vaccine Research reports on a phase 2 trial in Kenya that will assess the safety, tolerability and protective efficacy of the vaccine administered by direct venous inoculation (DVI) to infants 5-12 months of age, living in an area of high-malaria transmission

January 2017
Sanaria's PfSPZ Vaccine Provides High Level Defense Against Malaria In U.S. Navy and Army Clinical Investigation: Article; Sanaria Press Release

January 2017
Sanaria Featured in Selected NIAID Research Advances of 2016

September 2016
Sanaria® PfSPZ Vaccine Against Malaria Receives FDA Fast Track Designation: FiercePharma; Sanaria Press Release

June 2016
Sanaria's CEO, Dr. Stephen L. Hoffman, awarded the 2016 Weill Cornell Medicine Alumni Association Award of Distinction for his significant accomplishments as a physician, scientist and entrepreneur; Commencement Speech

May 2016
Nature Medicine publishes Sanaria's Research Article, Protection against malaria at 1 year and immune correlates following PfSPZ vaccination; Abstract; Sanaria Press Release; NIH Press Release

Older News

 

disclaimer     site map

copyright(c) 2003-2017, Sanaria Inc., all rights reserved